Patent: 10,279,037
✉ Email this page to a colleague
Summary for Patent: 10,279,037
| Title: | Methods and materials for modulating resistance to apoptosis using KLK6 antisense and MIRNA molecules |
| Abstract: | This document provides methods and materials involved in modulating a cell\'s ability to be resistant to apoptosis. For example, methods and materials for exposing cells to KLK6 polypeptides, or increased KLK6 polypeptide activity, to promote resistance to apoptosis are provided. In addition, methods and materials for reducing the ability of KLK6 polypeptides to promote resistance to apoptosis are provided. |
| Inventor(s): | Scarisbrick; Isobel A. (Rochester, MN) |
| Assignee: | Mayo Foundation for Medical Education and Research (Rochester, MN) |
| Application Number: | 15/584,822 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,279,037
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2030-09-30 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
